X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accesswire.com/856964/bionxt-solutions-announces-odf-cladribine-update-and-financing
https://www.accesswire.com/843970/bionxt-reports-commercialization-of-odf-cladribine-product-for-ms-next-steps
https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugs-dont-make-whos-essential-list-ebola-ms-drugs-added-2023-07-26/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-4-2023-52000.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-cladribine-1655269954.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-aprepitant-azilsartan-bupivacaine-cladribine-elrombopag-fosnetupitant-fostamatinib-ivacaftor-and-sodium-thiosulfate-1655270821.pdf
https://endpts.com/merck-kgaa-snatches-up-geneva-biotech-as-repurposed-chemotherapy-mission-strikes-a-chord/
https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-announces-72-mrd-negativity-rate-in-the-recently-completed-phase-1-study-of-actimab-a-in-combination-with-clag-m-for-patients-with-relapsed-or-refractory-aml-301444015.html
https://www.biospace.com/article/releases/mavenclad-and-174-cladribine-tablets-is-available-through-public-drug-plans-for-the-majority-of-eligible-canadians-with-relapsing-remitting-multiple-sclerosis/
https://www.prnewswire.com/news-releases/emd-serono-to-showcase-new-data-at-actrims-ectrims-msvirtual2020-meeting-furthering-innovation-in-multiple-sclerosis-301123847.html
https://www.prnewswire.com/news-releases/prime-therapeutics-and-emd-serono-ink-value-based-agreement-on-mavenclad-cladribine-tablets-301070979.html
https://www.fiercepharma.com/pharma/merck-kgaa-s-mavenclad-stakes-its-claim-massively-competitive-ms-market
http://www.pharmatimes.com/news/mavenclad_granted_accelerated_access_by_nice_1318168
https://www.fiercepharma.com/pharma/crowded-ms-market-merck-kgaa-s-mavenclad-now-offsets-rebif-decline
https://www.fiercepharma.com/marketing/ectrims-joining-novartis-and-roche-fight-for-ms-shares-merck-kgaa-touts-mavenclad-data
https://endpts.com/merck-kgaa-touts-fda-breakthrough-status-blockbuster-potential-in-bid-to-investors/
https://www.prnewswire.com/news-releases/alliancerx-walgreens-prime-issues-updated-list-of-new-specialty-drugs-300903210.html
https://www.fiercepharma.com/pharma/novartis-gilenya-staves-off-generic-challengers-after-federal-injunction
https://www.in-pharmatechnologist.com/Article/2019/04/09/Merck-KGaA-gets-FDA-approval-for-oral-MS-drug
https://www.fiercepharma.com/pharma/better-8-years-late-than-never-merck-kgaa-nabs-fda-nod-for-ms-drug-mavenclad
https://www.prnewswire.com/news-releases/fda-approves-mavenclad-cladribine-tablets-as-first-and-only-short-course-oral-treatment-for-relapsing-remitting-and-active-secondary-progressive-multiple-sclerosis-300821333.html
https://www.biospace.com/article/merck-announces-innovative-ms-treatment-mavenclad-cladribine-tablets-selected-for-rapid-uptake-by-the-accelerated-access-collaborative/
https://www.prnewswire.com/news-releases/up-to-10-years-of-follow-up-data-reaffirm-safety-profile-of-investigational-cladribine-tablets-873347245.html
https://www.prnewswire.com/news-releases/fda-accepts-file-for-cladribine-tablets-as-potential-treatment-for-relapsing-forms-of-multiple-sclerosis-829471781.html
http://www.pharmatimes.com/news/mercks_ms_treatment_shows_promise_in_new_data_1233973
https://www.fiercebiotech.com/biotech/astrazeneca-leukemia-drug-bags-priority-review-status-setting-up-third-quarter-approval
https://www.reuters.com/article/merckkgaa-results/update-1-chinese-competition-weighs-on-merck-kgaas-2018-outlook-idUSL5N1QQ0SR?rpc=401&
https://www.reuters.com/article/merck-multiplesclerosis-usa/germanys-merck-to-make-new-bid-to-enter-u-s-ms-pill-market-idUSL8N1OB4QD?rpc=401&
https://www.bloomberg.com/news/articles/2017-12-15/medicare-rigid-billing-system-leaves-gilead-cancer-drug-in-limbo
http://www.pharmatimes.com/news/new_analysis_backs_benefit-risk_profile_of_mercks_mavenclad_1209782
http://www.pharmatimes.com/news/mercks_ms_pill_mavenclad_launched_in_the_uk_and_ireland_1206047
https://www.pharmacompass.com/pdf/news/merck-serono-europes-mavenclad-cladribine-receives-approval-in-europe-1504927412.pdf
http://www.pharmatimes.com/news/eu_nod_for_mercks_ms_therapy_mavenlad_1203261
https://endpts.com/after-a-long-painful-revamp-merck-kgaa-scores-another-key-ok-for-once-defunct-ms-drug-cladribine/
http://www.pmlive.com/pharma_news/mercks_pharma_unit_faces_tougher_2017_as_fertility_boost_recedes_1176998
https://www.pharmacompass.com/pdf/news/zhejiang-hisun-pharmaceutical-co-ltd-yantou-campus-fails-edqm-inspection-1483966941.pdf
http://www.fiercebiotech.com/story/pharma-rd-underachiever-merck-kgaa-gambles-250m-phiii-comeback/2015-12-10
http://www.fiercepharma.com/story/merck-kgaa-reworks-healthcare-exec-team-new-coo-cmo/2015-09-15
http://www.reuters.com/article/2015/09/11/us-merck-cladribine-idUSKCN0RB0HF20150911
Market Place
Share 
